Comparing	O
[P1]	O
Paclitaxel	O
-	O
Carboplatin	O
[P2]	O
with	O
Paclitaxel	O
-	O
Cisplatin	O
as	O
the	O
Front	O
-	O
Line	O
Chemotherapy	O
for	O
Patients	O
with	O
FIGO	O
IIIC	O
Serous	O
-	O
Type	O
Tubo	O
-	O
Ovarian	O
Cancer	O
Comparing	O
Paclitaxel	O
-	O
Carboplatin	O
with	O
Paclitaxel	O
-	O
Cisplatin	O
as	O
the	O
Front	O
-	O
Line	O
Chemotherapy	O
for	O
Patients	O
with	O
FIGO	O
IIIC	O
Serous	O
-	O
Type	O
Tubo	O
-	O
Ovarian	O
Cancer	O
26	O
March	O
2020	O
26	O
March	O
2020	O
Chen	O
-	O
YuHuang	O

Comparing	O
Paclitaxel	O
-	O
Carboplatin	O
with	O
[P1]	O
Paclitaxel	O
-	O
Cisplatin	O
[P2]	O
as	O
the	O
Front	O
-	O
Line	O
Chemotherapy	O
for	O
Patients	O
with	O
FIGO	O
IIIC	O
Serous	O
-	O
Type	O
Tubo	O
-	O
Ovarian	O
Cancer	O
Comparing	O
Paclitaxel	O
-	O
Carboplatin	O
with	O
Paclitaxel	O
-	O
Cisplatin	O
as	O
the	O
Front	O
-	O
Line	O
Chemotherapy	O
for	O
Patients	O
with	O
FIGO	O
IIIC	O
Serous	O
-	O
Type	O
Tubo	O
-	O
Ovarian	O
Cancer	O
26	O
March	O
2020	O
26	O
March	O
2020	O
Chen	O
-	O
YuHuang	O

Comparing	O
Paclitaxel	O
-	O
Carboplatin	O
with	O
Paclitaxel	O
-	O
Cisplatin	O
as	O
the	O
Front	O
-	O
Line	O
Chemotherapy	O
for	O
Patients	O
with	O
FIGO	O
IIIC	O
Serous	O
-	O
Type	O
Tubo	O
-	O
Ovarian	O
Cancer	O
Comparing	O
[P1]	O
Paclitaxel	O
-	O
Carboplatin	O
[P2]	O
with	O
Paclitaxel	O
-	O
Cisplatin	O
as	O
the	O
Front	O
-	O
Line	O
Chemotherapy	O
for	O
Patients	O
with	O
FIGO	O
IIIC	O
Serous	O
-	O
Type	O
Tubo	O
-	O
Ovarian	O
Cancer	O
26	O
March	O
2020	O
26	O
March	O
2020	O
Chen	O
-	O
YuHuang	O

Comparing	O
Paclitaxel	O
-	O
Carboplatin	O
with	O
Paclitaxel	O
-	O
Cisplatin	O
as	O
the	O
Front	O
-	O
Line	O
Chemotherapy	O
for	O
Patients	O
with	O
FIGO	O
IIIC	O
Serous	O
-	O
Type	O
Tubo	O
-	O
Ovarian	O
Cancer	O
Comparing	O
Paclitaxel	O
-	O
Carboplatin	O
with	O
[P1]	O
Paclitaxel	O
-	O
Cisplatin	O
[P2]	O
as	O
the	O
Front	O
-	O
Line	O
Chemotherapy	O
for	O
Patients	O
with	O
FIGO	O
IIIC	O
Serous	O
-	O
Type	O
Tubo	O
-	O
Ovarian	O
Cancer	O
26	O
March	O
2020	O
26	O
March	O
2020	O
Chen	O
-	O
YuHuang	O

Comparing	O
[P1]	O
Paclitaxel	O
-	O
Carboplatin	O
[P2]	O
with	O
Paclitaxel	O
-	O
Cisplatin	O
as	O
the	O
Front	O
-	O
Line	O
Chemotherapy	O
for	O
Patients	O
with	O
FIGO	O
IIIC	O
Serous	O
-	O
Type	O
Tubo	O
-	O
Ovarian	O
Cancer	O
26	O
March	O
2020	O
10.3390	O
/	O
ijerph17072213	O

Comparing	O
Paclitaxel	O
-	O
Carboplatin	O
with	O
[P1]	O
Paclitaxel	O
-	O
Cisplatin	O
[P2]	O
as	O
the	O
Front	O
-	O
Line	O
Chemotherapy	O
for	O
Patients	O
with	O
FIGO	O
IIIC	O
Serous	O
-	O
Type	O
Tubo	O
-	O
Ovarian	O
Cancer	O
26	O
March	O
2020	O
10.3390	O
/	O
ijerph17072213	O

Comparing	O
[P1]	O
Paclitaxel	O
-	O
Carboplatin	O
[P2]	O
with	O
Paclitaxel	O
-	O
Cisplatin	O
as	O
the	O
Front	O
-	O
Line	O
Chemotherapy	O
for	O
Patients	O
with	O
FIGO	O
IIIC	O
Serous	O
-	O
Type	O
Tubo	O
-	O
Ovarian	O
Cancer	O
Chen	O
-	O
YuHuang	O

Comparing	O
Paclitaxel	O
-	O
Carboplatin	O
with	O
[P1]	O
Paclitaxel	O
-	O
Cisplatin	O
[P2]	O
as	O
the	O
Front	O
-	O
Line	O
Chemotherapy	O
for	O
Patients	O
with	O
FIGO	O
IIIC	O
Serous	O
-	O
Type	O
Tubo	O
-	O
Ovarian	O
Cancer	O
Chen	O
-	O
YuHuang	O

Taiwan	O
104	O
Taipei	O
Taiwan	O
Comparing	O
[P1]	O
Paclitaxel	O
-	O
Carboplatin	O
[P2]	O
with	O
Paclitaxel	O
-	O
Cisplatin	O
as	O
the	O
Front	O
-	O
Line	O
Chemotherapy	O
for	O
Patients	O
with	O
FIGO	O
IIIC	O
Serous	O
-	O
Type	O
Tubo	O
-	O
Ovarian	O
Cancer	O
26	O
March	O
2020	O
26	O
March	O
2020	O
26	O
March	O
2020	O
10.3390	O
/	O
ijerph17072213	O
Received	O
:	O

Taiwan	O
104	O
Taipei	O
Taiwan	O
Comparing	O
Paclitaxel	O
-	O
Carboplatin	O
with	O
[P1]	O
Paclitaxel	O
-	O
Cisplatin	O
[P2]	O
as	O
the	O
Front	O
-	O
Line	O
Chemotherapy	O
for	O
Patients	O
with	O
FIGO	O
IIIC	O
Serous	O
-	O
Type	O
Tubo	O
-	O
Ovarian	O
Cancer	O
26	O
March	O
2020	O
26	O
March	O
2020	O
26	O
March	O
2020	O
10.3390	O
/	O
ijerph17072213	O
Received	O
:	O

In	O
order	O
to	O
evaluate	O
the	O
effects	O
and	O
safety	O
of	O
dose	O
-	O
dense	O
of	O
[P1]	O
paclitaxel	O
combining	O
[P2]	O
with	O
either	O
cisplatin	O
or	O
carboplatin	O
,	O
the	O
following	O
retrospective	O
study	O
was	O
conducted	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
effects	O
and	O
safety	O
of	O
dose	O
-	O
dense	O
of	O
paclitaxel	O
combining	O
with	O
either	O
cisplatin	O
or	O
[P1]	O
carboplatin	O
[P2]	O
,	O
the	O
following	O
retrospective	O
study	O
was	O
conducted	O
.	O

Patients	O
with	O
FIGO	O
IIIC	O
serous	O
-	O
type	O
ETOC	O
and	O
PPSC	O
treated	O
either	O
with	O
triweekly	B-arm_dosage
[P1]	O
cisplatin	O
[P2]	O
(	B-arm_dosage
20	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
plus	I-arm_dosage
dose	I-arm_dosage
-	I-arm_dosage
dense	I-arm_dosage
weekly	I-arm_dosage
paclitaxel	O
(	B-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
or	O
triweekly	O
carboplatin	O
(	O
AUC	O
5	O
)	O
plus	O
dose	O
-	O
dense	O
weekly	O
paclitaxel	O
(	O
80	O
mg	O
/	O
m	O
2	O
)	O
as	O
postoperative	O
adjuvant	O
chemotherapy	O
after	O
PCS	O
were	O
retrospectively	O
reviewed	O
.	O

Patients	O
with	O
FIGO	O
IIIC	O
serous	O
-	O
type	O
ETOC	O
and	O
PPSC	O
treated	O
either	O
with	O
triweekly	B-arm_dosage
cisplatin	O
(	B-arm_dosage
20	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
plus	I-arm_dosage
dose	I-arm_dosage
-	I-arm_dosage
dense	I-arm_dosage
weekly	I-arm_dosage
[P1]	O
paclitaxel	O
[P2]	O
(	B-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
or	O
triweekly	O
carboplatin	O
(	O
AUC	O
5	O
)	O
plus	O
dose	O
-	O
dense	O
weekly	O
paclitaxel	O
(	O
80	O
mg	O
/	O
m	O
2	O
)	O
as	O
postoperative	O
adjuvant	O
chemotherapy	O
after	O
PCS	O
were	O
retrospectively	O
reviewed	O
.	O

Patients	O
with	O
FIGO	O
IIIC	O
serous	O
-	O
type	O
ETOC	O
and	O
PPSC	O
treated	O
either	O
with	O
triweekly	O
cisplatin	O
(	O
20	O
mg	O
/	O
m	O
2	O
)	O
plus	O
dose	O
-	O
dense	O
weekly	O
paclitaxel	O
(	B-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
or	O
triweekly	B-arm_dosage
[P1]	O
carboplatin	O
[P2]	O
(	B-arm_dosage
AUC	I-arm_dosage
5	I-arm_dosage
)	I-arm_dosage
plus	I-arm_dosage
dose	I-arm_dosage
-	I-arm_dosage
dense	I-arm_dosage
weekly	I-arm_dosage
paclitaxel	O
(	B-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
as	O
postoperative	O
adjuvant	O
chemotherapy	O
after	O
PCS	O
were	O
retrospectively	O
reviewed	O
.	O

Patients	O
with	O
FIGO	O
IIIC	O
serous	O
-	O
type	O
ETOC	O
and	O
PPSC	O
treated	O
either	O
with	O
triweekly	O
cisplatin	O
(	O
20	O
mg	O
/	O
m	O
2	O
)	O
plus	O
dose	O
-	O
dense	O
weekly	O
paclitaxel	O
(	B-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
or	O
triweekly	B-arm_dosage
carboplatin	O
(	B-arm_dosage
AUC	I-arm_dosage
5	I-arm_dosage
)	I-arm_dosage
plus	I-arm_dosage
dose	I-arm_dosage
-	I-arm_dosage
dense	I-arm_dosage
weekly	I-arm_dosage
[P1]	O
paclitaxel	O
[P2]	O
(	B-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
as	O
postoperative	O
adjuvant	O
chemotherapy	O
after	O
PCS	O
were	O
retrospectively	O
reviewed	O
.	O

However	O
,	O
nearly	O
all	O
dose	O
-	O
dense	O
[P1]	O
paclitaxel	O
[P2]	O
-	O
platinum	O
combination	O
chemotherapy	O
regimens	O
used	O
as	O
the	O
front	O
-	O
line	O
postoperative	O
adjuvant	O
therapy	O
are	O
focused	O
on	O
the	O
dose	O
-	O
dense	O
paclitaxel	O
,	O
without	O
consideration	O
of	O
either	O
the	O
platinum	O
compounds	O
or	O
the	O
dose	O
-	O
dense	O
agents	O
.	O

However	O
,	O
nearly	O
all	O
dose	O
-	O
dense	O
paclitaxel	O
-	O
platinum	O
combination	O
chemotherapy	O
regimens	O
used	O
as	O
the	O
front	O
-	O
line	O
postoperative	O
adjuvant	O
therapy	O
are	O
focused	O
on	O
the	O
dose	O
-	O
dense	O
[P1]	O
paclitaxel	O
[P2]	O
,	O
without	O
consideration	O
of	O
either	O
the	O
platinum	O
compounds	O
or	O
the	O
dose	O
-	O
dense	O
agents	O
.	O

After	O
institutional	O
review	O
board	O
approval	O
(	O
VGHIRB	O
2019	O
-	O
07	O
-	O
039BC	O
)	O
,	O
all	O
patients	O
between	O
January	O
2010	O
and	O
December	O
2016	O
who	O
fulfilled	O
the	O
following	O
inclusion	O
(	O
International	O
Federation	O
of	O
Gynecology	O
and	O
Obstetrics	O
(	O
FIGO	O
)	O
stage	O
IIIC	O
histologically	O
confirmed	O
high	O
-	O
grade	O
serous	O
-	O
type	O
ETOC	O
and	O
PPSC	O
,	O
an	O
initial	O
PCS	O
,	O
a	O
total	O
of	O
six	B-arm_dosage
cycles	I-arm_dosage
of	I-arm_dosage
weekly	I-arm_dosage
[P1]	O
paclitaxel	O
[P2]	O
[	B-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
]	I-arm_dosage
plus	O
either	O
triweekly	B-arm_dosage
cisplatin	O
[	B-arm_dosage
20	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
]	I-arm_dosage
or	O
triweekly	O
carboplatin	O
[	O
AUC	O
5	O
]	O
regimen	O
)	O
and	O
exclusion	O
(	O
NACT	O
,	O
other	O
newly	O
diagnosed	O
cancer	O
,	O
previous	O
chemotherapy	O
,	O
or	O
radiotherapy	O
in	O
the	O
past	O
two	O
years	O
;	O

After	O
institutional	O
review	O
board	O
approval	O
(	O
VGHIRB	O
2019	O
-	O
07	O
-	O
039BC	O
)	O
,	O
all	O
patients	O
between	O
January	O
2010	O
and	O
December	O
2016	O
who	O
fulfilled	O
the	O
following	O
inclusion	O
(	O
International	O
Federation	O
of	O
Gynecology	O
and	O
Obstetrics	O
(	O
FIGO	O
)	O
stage	O
IIIC	O
histologically	O
confirmed	O
high	O
-	O
grade	O
serous	O
-	O
type	O
ETOC	O
and	O
PPSC	O
,	O
an	O
initial	O
PCS	O
,	O
a	O
total	O
of	O
six	B-arm_dosage
cycles	I-arm_dosage
of	I-arm_dosage
weekly	I-arm_dosage
paclitaxel	O
[	B-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
]	I-arm_dosage
plus	O
either	O
triweekly	B-arm_dosage
[P1]	O
cisplatin	O
[P2]	O
[	B-arm_dosage
20	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
]	I-arm_dosage
or	O
triweekly	O
carboplatin	O
[	O
AUC	O
5	O
]	O
regimen	O
)	O
and	O
exclusion	O
(	O
NACT	O
,	O
other	O
newly	O
diagnosed	O
cancer	O
,	O
previous	O
chemotherapy	O
,	O
or	O
radiotherapy	O
in	O
the	O
past	O
two	O
years	O
;	O

After	O
institutional	O
review	O
board	O
approval	O
(	O
VGHIRB	O
2019	O
-	O
07	O
-	O
039BC	O
)	O
,	O
all	O
patients	O
between	O
January	O
2010	O
and	O
December	O
2016	O
who	O
fulfilled	O
the	O
following	O
inclusion	O
(	O
International	O
Federation	O
of	O
Gynecology	O
and	O
Obstetrics	O
(	O
FIGO	O
)	O
stage	O
IIIC	O
histologically	O
confirmed	O
high	O
-	O
grade	O
serous	O
-	O
type	O
ETOC	O
and	O
PPSC	O
,	O
an	O
initial	O
PCS	O
,	O
a	O
total	O
of	O
six	O
cycles	O
of	O
weekly	O
paclitaxel	O
[	B-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
]	I-arm_dosage
plus	O
either	O
triweekly	O
cisplatin	O
[	B-arm_dosage
20	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
]	I-arm_dosage
or	O
triweekly	B-arm_dosage
[P1]	O
carboplatin	O
[P2]	O
[	B-arm_dosage
AUC	I-arm_dosage
5	I-arm_dosage
]	I-arm_dosage
regimen	I-arm_dosage
)	I-arm_dosage
and	O
exclusion	O
(	O
NACT	O
,	O
other	O
newly	O
diagnosed	O
cancer	O
,	O
previous	O
chemotherapy	O
,	O
or	O
radiotherapy	O
in	O
the	O
past	O
two	O
years	O
;	O

Since	O
both	O
cisplatin	O
and	O
[P1]	O
carboplatin	O
[P2]	O
are	O
available	O
in	O
our	O
department	O
,	O
the	O
selection	O
of	O
cisplatin	O
or	O
carboplatin	O
was	O
based	O
on	O
the	O
patient	O
's	O
will	O
after	O
shared	O
decision	O
making	O
.	O

Since	O
both	O
cisplatin	O
and	O
carboplatin	O
are	O
available	O
in	O
our	O
department	O
,	O
the	O
selection	O
of	O
[P1]	O
cisplatin	O
[P2]	O
or	O
carboplatin	O
was	O
based	O
on	O
the	O
patient	O
's	O
will	O
after	O
shared	O
decision	O
making	O
.	O

Since	O
both	O
cisplatin	O
and	O
carboplatin	O
are	O
available	O
in	O
our	O
department	O
,	O
the	O
selection	O
of	O
cisplatin	O
or	O
[P1]	O
carboplatin	O
[P2]	O
was	O
based	O
on	O
the	O
patient	O
's	O
will	O
after	O
shared	O
decision	O
making	O
.	O

All	O
patients	O
underwent	O
PCS	O
initially	O
and	O
then	O
were	O
treated	O
with	O
weekly	O
[P1]	O
paclitaxel	O
[P2]	O
(	O
80	O
mg	O
/	O
m	O
2	O
)	O
plus	O
either	O
triweekly	B-arm_dosage
cisplatin	O
(	B-arm_dosage
20	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
or	O
triweekly	O
carboplatin	O
(	B-arm_dosage
AUC	I-arm_dosage
5	I-arm_dosage
)	I-arm_dosage
.	O

All	O
patients	O
underwent	O
PCS	O
initially	O
and	O
then	O
were	O
treated	O
with	O
weekly	O
paclitaxel	O
(	O
80	O
mg	O
/	O
m	O
2	O
)	O
plus	O
either	O
triweekly	B-arm_dosage
[P1]	O
cisplatin	O
[P2]	O
(	B-arm_dosage
20	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
or	O
triweekly	O
carboplatin	O
(	B-arm_dosage
AUC	I-arm_dosage
5	I-arm_dosage
)	I-arm_dosage
.	O

All	O
patients	O
underwent	O
PCS	O
initially	O
and	O
then	O
were	O
treated	O
with	O
weekly	O
paclitaxel	O
(	B-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
plus	O
either	O
triweekly	O
cisplatin	O
(	B-arm_dosage
20	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
or	O
triweekly	B-arm_dosage
[P1]	O
carboplatin	O
[P2]	O
(	B-arm_dosage
AUC	I-arm_dosage
5	I-arm_dosage
)	I-arm_dosage
.	O

[P1]	O
Paclitaxel	O
[P2]	O
was	O
administered	B-arm_dosage
over	I-arm_dosage
2	I-arm_dosage
h	I-arm_dosage
intravenously	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
,	I-arm_dosage
8	I-arm_dosage
,	I-arm_dosage
and	I-arm_dosage
15	I-arm_dosage
,	O
and	O
either	O
cisplatin	O
for	O
1	B-arm_dosage
h	I-arm_dosage
or	O
carboplatin	O
for	O
1	O
h	O
on	O
day	O
1	O
was	O
infused	O
intravenously	O
.	O

Paclitaxel	O
was	O
administered	B-arm_dosage
over	I-arm_dosage
2	I-arm_dosage
h	I-arm_dosage
intravenously	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
,	I-arm_dosage
8	I-arm_dosage
,	I-arm_dosage
and	I-arm_dosage
15	I-arm_dosage
,	O
and	O
either	O
[P1]	O
cisplatin	O
[P2]	O
for	O
1	B-arm_dosage
h	I-arm_dosage
or	O
carboplatin	O
for	O
1	O
h	O
on	O
day	O
1	O
was	O
infused	O
intravenously	O
.	O

Paclitaxel	O
was	O
administered	O
over	O
2	O
h	O
intravenously	O
on	O
days	O
1	O
,	O
8	O
,	O
and	O
15	O
,	O
and	O
either	O
cisplatin	O
for	O
1	O
h	O
or	O
[P1]	O
carboplatin	O
[P2]	O
for	O
1	B-arm_dosage
h	I-arm_dosage
on	I-arm_dosage
day	I-arm_dosage
1	I-arm_dosage
was	I-arm_dosage
infused	I-arm_dosage
intravenously	I-arm_dosage
.	O

If	O
a	O
three	O
-	O
fold	O
increase	O
in	O
liver	O
enzymes	O
of	O
patients	O
was	O
detected	O
,	O
[P1]	O
paclitaxel	O
[P2]	O
(	B-arm_dosage
60	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
was	O
used	O
.	O

The	O
[P1]	O
cisplatin	O
[P2]	O
dose	O
was	O
decreased	O
to	O
half	O
dosage	O
if	O
the	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
eGFR	O
)	O
was	O
decreased	O
to	O
45	O
-	O
60	O
ml	O
/	O
min	O
,	O
which	O
was	O
calculated	O
using	O
the	O
Cockcroft	O
-	O
Gault	O
formula	O
[	O
122][123][124	O
]	O
.	O

A	O
total	O
of	O
40	O
women	O
with	O
International	O
Federation	O
of	O
Gynecology	O
and	O
Obstetrics	O
(	O
FIGO	O
)	O
stage	O
IIIC	O
ETOC	O
or	O
PPSC	O
were	O
analyzed	O
,	O
including	O
18	O
treated	O
with	O
[P1]	O
paclitaxel	O
-	O
cisplatin	O
[P2]	O
and	O
the	O
remaining	O
22	O
treated	O
with	O
paclitaxel	O
-	O
carboplatin	O
.	O

A	O
total	O
of	O
40	O
women	O
with	O
International	O
Federation	O
of	O
Gynecology	O
and	O
Obstetrics	O
(	O
FIGO	O
)	O
stage	O
IIIC	O
ETOC	O
or	O
PPSC	O
were	O
analyzed	O
,	O
including	O
18	O
treated	O
with	O
paclitaxel	O
-	O
cisplatin	O
and	O
the	O
remaining	O
22	O
treated	O
with	O
[P1]	O
paclitaxel	O
-	O
carboplatin	O
[P2]	O
.	O

Optimal	O
PCS	O
was	O
achieved	O
in	O
55	O
%	O
in	O
overall	O
,	O
and	O
54.5	O
%	O
and	O
55.6	O
%	O
in	O
the	O
[P1]	O
paclitaxel	O
-	O
carboplatin	O
[P2]	O
and	O
paclitaxel	O
-	O
cisplatin	O
groups	O
,	O
respectively	O
.	O

Optimal	O
PCS	O
was	O
achieved	O
in	O
55	O
%	O
in	O
overall	O
,	O
and	O
54.5	O
%	O
and	O
55.6	O
%	O
in	O
the	O
paclitaxel	O
-	O
carboplatin	O
and	O
[P1]	O
paclitaxel	O
-	O
cisplatin	O
[P2]	O
groups	O
,	O
respectively	O
.	O

Patients	O
in	O
the	O
[P1]	O
paclitaxel	O
-	O
carboplatin	O
[P2]	O
group	O
had	O
a	O
higher	O
risk	O
of	O
a	O
prolonged	O
time	O
to	O
finish	O
6	O
cycles	O
of	O
the	O
front	O
-	O
line	O
chemotherapy	O
after	O
PCS	O
than	O
those	O
in	O
paclitaxel	O
-	O
cisplatin	O
group	O
(	O
45.5	O
%	O
versus	O
11.1	O
%	O
,	O
p	O
=	O
0.018	O
)	O
,	O
which	O
reached	O
the	O
statistically	O
significant	O
difference	O
.	O

Patients	O
in	O
the	O
paclitaxel	O
-	O
carboplatin	O
group	O
had	O
a	O
higher	O
risk	O
of	O
a	O
prolonged	O
time	O
to	O
finish	O
6	O
cycles	O
of	O
the	O
front	O
-	O
line	O
chemotherapy	O
after	O
PCS	O
than	O
those	O
in	O
[P1]	O
paclitaxel	O
-	O
cisplatin	O
[P2]	O
group	O
(	O
45.5	O
%	O
versus	O
11.1	O
%	O
,	O
p	O
=	O
0.018	O
)	O
,	O
which	O
reached	O
the	O
statistically	O
significant	O
difference	O
.	O

Patients	O
who	O
were	O
treated	O
with	O
the	O
[P1]	O
paclitaxel	O
-	O
carboplatin	O
[P2]	O
regimen	O
had	O
a	O
higher	O
risk	O
of	O
development	O
of	O
neutropenia	O
than	O
those	O
with	O
the	O
paclitaxel	O
-	O
cisplatin	O
regimen	O
.	O

Patients	O
who	O
were	O
treated	O
with	O
the	O
paclitaxel	O
-	O
carboplatin	O
regimen	O
had	O
a	O
higher	O
risk	O
of	O
development	O
of	O
neutropenia	O
than	O
those	O
with	O
the	O
[P1]	O
paclitaxel	O
-	O
cisplatin	O
[P2]	O
regimen	O
.	O

In	O
addition	O
,	O
grade	O
3/4	O
neutropenia	O
occurred	O
more	O
frequently	O
in	O
patients	O
treated	O
with	O
the	O
[P1]	O
paclitaxel	O
-	O
carboplatin	O
[P2]	O
regimen	O
compared	O
to	O
that	O
in	O
patients	O
with	O
the	O
paclitaxel	O
-	O
cisplatin	O
regimen	O
.	O

In	O
addition	O
,	O
grade	O
3/4	O
neutropenia	O
occurred	O
more	O
frequently	O
in	O
patients	O
treated	O
with	O
the	O
paclitaxel	O
-	O
carboplatin	O
regimen	O
compared	O
to	O
that	O
in	O
patients	O
with	O
the	O
[P1]	O
paclitaxel	O
-	O
cisplatin	O
[P2]	O
regimen	O
.	O

In	O
current	O
study	O
,	O
[P1]	O
cisplatin	O
[P2]	O
-	O
related	O
AEs	O
,	O
such	O
as	O
renal	O
toxicity	O
,	O
neurotoxicity	O
,	O
nausea	O
,	O
or	O
vomiting	O
were	O
mild	O
or	O
absent	O
,	O
as	O
shown	O
in	O
Table	O
2	O
.	O

Adverse	O
events	O
the	O
patients	O
with	O
FIGO	O
IIIC	O
serous	O
type	O
epithelial	O
tubo	O
-	O
ovarian	O
cancer	O
,	O
or	O
primary	O
peritoneal	O
carcinoma	O
treated	O
with	O
weekly	O
[P1]	O
paclitaxel	O
[P2]	O
(	B-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
plus	O
either	O
carboplatin	O
(	O
AUC	O
5	O
)	O
or	O
cisplatin	O
(	B-arm_dosage
20	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
combination	O
chemotherapy	O
triweekly	B-arm_dosage
.	O

Adverse	O
events	O
the	O
patients	O
with	O
FIGO	O
IIIC	O
serous	O
type	O
epithelial	O
tubo	O
-	O
ovarian	O
cancer	O
,	O
or	O
primary	O
peritoneal	O
carcinoma	O
treated	O
with	O
weekly	O
paclitaxel	O
(	O
80	O
mg	O
/	O
m	O
2	O
)	O
plus	O
either	O
[P1]	O
carboplatin	O
[P2]	O
(	B-arm_dosage
AUC	I-arm_dosage
5	I-arm_dosage
)	I-arm_dosage
or	O
cisplatin	O
(	O
20	O
mg	O
/	O
m	O
2	O
)	O
combination	O
chemotherapy	O
triweekly	O
.	O

Adverse	O
events	O
the	O
patients	O
with	O
FIGO	O
IIIC	O
serous	O
type	O
epithelial	O
tubo	O
-	O
ovarian	O
cancer	O
,	O
or	O
primary	O
peritoneal	O
carcinoma	O
treated	O
with	O
weekly	O
paclitaxel	O
(	B-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
plus	O
either	O
carboplatin	O
(	O
AUC	O
5	O
)	O
or	O
[P1]	O
cisplatin	O
[P2]	O
(	B-arm_dosage
20	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
combination	O
chemotherapy	O
triweekly	B-arm_dosage
.	O

As	O
was	O
presented	O
in	O
Figure	O
1	O
,	O
the	O
median	O
PFS	O
was	O
25.0	B-arm_efficacy_results
months	I-arm_efficacy_results
in	O
patients	O
treated	O
with	O
the	O
[P1]	O
paclitaxel	O
-	O
carboplatin	O
[P2]	O
regimen	O
,	O
and	O
30.0	O
months	O
in	O
patients	O
treated	O
with	O
the	O
paclitaxel	O
-	O
cisplatin	O
regimen	O
,	O
without	O
a	O
statistically	O
significant	O
difference	O
.	O

As	O
was	O
presented	O
in	O
Figure	O
1	O
,	O
the	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
was	O
25.0	O
months	O
in	O
patients	O
treated	O
with	O
the	O
paclitaxel	O
-	O
carboplatin	O
regimen	O
,	O
and	O
30.0	B-arm_efficacy_results
months	I-arm_efficacy_results
in	O
patients	O
treated	O
with	O
the	O
[P1]	O
paclitaxel	O
-	O
cisplatin	O
[P2]	O
regimen	O
,	O
without	O
a	O
statistically	O
significant	O
difference	O
.	O

The	O
median	O
OS	O
was	O
55.0	O
months	O
and	O
58.5	O
months	O
in	O
patients	O
treated	O
with	O
[P1]	O
paclitaxel	O
-	O
carboplatin	O
[P2]	O
and	O
paclitaxel	O
-	O
cisplatin	O
regimens	O
,	O
respectively	O
(	O
Figure	O
2	O
)	O
.	O

The	O
median	O
OS	O
was	O
55.0	O
months	O
and	O
58.5	O
months	O
in	O
patients	O
treated	O
with	O
paclitaxel	O
-	O
carboplatin	O
and	O
[P1]	O
paclitaxel	O
-	O
cisplatin	O
[P2]	O
regimens	O
,	O
respectively	O
(	O
Figure	O
2	O
)	O
.	O

Adverse	O
events	O
the	O
patients	O
with	O
FIGO	O
IIIC	O
serous	O
type	O
epithelial	O
tubo	O
-	O
ovarian	O
cancer	O
,	O
or	O
primary	O
peritoneal	O
carcinoma	O
treated	O
with	O
weekly	O
[P1]	O
paclitaxel	O
[P2]	O
(	B-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
plus	O
either	O
carboplatin	O
(	O
AUC	O
5	O
)	O
or	O
cisplatin	O
(	B-arm_dosage
20mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
combination	O
chemotherapy	O
triweekly	B-arm_dosage
.	O

Adverse	O
events	O
the	O
patients	O
with	O
FIGO	O
IIIC	O
serous	O
type	O
epithelial	O
tubo	O
-	O
ovarian	O
cancer	O
,	O
or	O
primary	O
peritoneal	O
carcinoma	O
treated	O
with	O
weekly	O
paclitaxel	O
(	O
80	O
mg	O
/	O
m	O
2	O
)	O
plus	O
either	O
[P1]	O
carboplatin	O
[P2]	O
(	B-arm_dosage
AUC	I-arm_dosage
5	I-arm_dosage
)	I-arm_dosage
or	O
cisplatin	O
(	O
20mg	O
/	O
m	O
2	O
)	O
combination	O
chemotherapy	O
triweekly	O
.	O

Adverse	O
events	O
the	O
patients	O
with	O
FIGO	O
IIIC	O
serous	O
type	O
epithelial	O
tubo	O
-	O
ovarian	O
cancer	O
,	O
or	O
primary	O
peritoneal	O
carcinoma	O
treated	O
with	O
weekly	O
paclitaxel	O
(	B-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
plus	O
either	O
carboplatin	O
(	O
AUC	O
5	O
)	O
or	O
[P1]	O
cisplatin	O
[P2]	O
(	B-arm_dosage
20mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
combination	O
chemotherapy	O
triweekly	B-arm_dosage
.	O

As	O
was	O
presented	O
in	O
Figure	O
1	O
,	O
the	O
median	O
PFS	O
was	O
25.0	B-arm_efficacy_results
months	I-arm_efficacy_results
in	O
patients	O
treated	O
with	O
the	O
[P1]	O
paclitaxel	O
-	O
carboplatin	O
[P2]	O
regimen	O
,	O
and	O
30.0	O
months	O
in	O
patients	O
treated	O
with	O
the	O
paclitaxel	O
-	O
cisplatin	O
regimen	O
,	O
without	O
a	O
statistically	O
significant	O
difference	O
.	O

As	O
was	O
presented	O
in	O
Figure	O
1	O
,	O
the	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
was	O
25.0	O
months	O
in	O
patients	O
treated	O
with	O
the	O
paclitaxel	O
-	O
carboplatin	O
regimen	O
,	O
and	O
30.0	B-arm_efficacy_results
months	I-arm_efficacy_results
in	O
patients	O
treated	O
with	O
the	O
[P1]	O
paclitaxel	O
-	O
cisplatin	O
[P2]	O
regimen	O
,	O
without	O
a	O
statistically	O
significant	O
difference	O
.	O

The	O
median	O
OS	O
was	O
55.0	O
months	O
and	O
58.5	O
months	O
in	O
patients	O
treated	O
with	O
[P1]	O
paclitaxel	O
-	O
carboplatin	O
[P2]	O
and	O
paclitaxel	O
-	O
cisplatin	O
regimens	O
,	O
respectively	O
(	O
Figure	O
2	O
)	O
.	O

The	O
median	O
OS	O
was	O
55.0	O
months	O
and	O
58.5	O
months	O
in	O
patients	O
treated	O
with	O
paclitaxel	O
-	O
carboplatin	O
and	O
[P1]	O
paclitaxel	O
-	O
cisplatin	O
[P2]	O
regimens	O
,	O
respectively	O
(	O
Figure	O
2	O
)	O
.	O

The	O
main	O
findings	O
of	O
the	O
current	O
study	O
showed	O
that	O
both	O
regimens	O
could	O
be	O
successfully	O
used	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
FIGO	O
IIIC	O
ETOC	O
or	O
PPSC	O
,	O
offering	O
30	B-arm_efficacy_results
and	O
25	O
months	O
of	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
in	O
the	O
[P1]	O
paclitaxel	O
-	O
cisplatin	O
[P2]	O
and	O
paclitaxel	O
-	O
carboplatin	O
groups	O
,	O
respectively	O
.	O

The	O
main	O
findings	O
of	O
the	O
current	O
study	O
showed	O
that	O
both	O
regimens	O
could	O
be	O
successfully	O
used	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
FIGO	O
IIIC	O
ETOC	O
or	O
PPSC	O
,	O
offering	O
30	O
and	O
25	B-arm_efficacy_results
months	I-arm_efficacy_results
of	O
median	O
PFS	O
in	O
the	O
paclitaxel	O
-	O
cisplatin	O
and	O
[P1]	O
paclitaxel	O
-	O
carboplatin	O
[P2]	O
groups	O
,	O
respectively	O
.	O

The	O
median	O
OS	O
was	O
58.5	O
months	O
in	O
the	O
[P1]	O
paclitaxel	O
-	O
cisplatin	O
[P2]	O
group	O
and	O
55.0	O
months	O
in	O
the	O
paclitaxel	O
-	O
carboplatin	O
group	O
.	O

The	O
median	O
OS	O
was	O
58.5	O
months	O
in	O
the	O
paclitaxel	O
-	O
cisplatin	O
group	O
and	O
55.0	O
months	O
in	O
the	O
[P1]	O
paclitaxel	O
-	O
carboplatin	O
[P2]	O
group	O
.	O

Although	O
neither	O
PFS	B-arm_efficacy_metric
nor	O
OS	O
reached	O
the	O
statistically	O
significant	O
difference	O
,	O
it	O
seemed	O
to	O
be	O
little	O
better	O
in	O
patients	O
treated	O
with	O
the	O
[P1]	O
paclitaxel	O
-	O
cisplatin	O
[P2]	O
regimen	O
compared	O
to	O
those	O
treated	O
with	O
the	O
paclitaxel	O
-	O
carboplatin	O
regimen	O
.	O

Although	O
neither	O
PFS	O
nor	O
OS	O
reached	O
the	O
statistically	O
significant	O
difference	O
,	O
it	O
seemed	O
to	O
be	O
little	O
better	O
in	O
patients	O
treated	O
with	O
the	O
paclitaxel	O
-	O
cisplatin	O
regimen	O
compared	O
to	O
those	O
treated	O
with	O
the	O
[P1]	O
paclitaxel	O
-	O
carboplatin	O
[P2]	O
regimen	O
.	O

However	O
,	O
to	O
compare	O
the	O
frequency	O
and	O
severity	O
of	O
AEs	O
,	O
we	O
found	O
that	O
patients	O
in	O
the	O
[P1]	O
paclitaxel	O
-	O
carboplatin	O
[P2]	O
group	O
had	O
more	O
AEs	O
than	O
those	O
in	O
paclitaxel	O
-	O
cisplatin	O
group	O
did	O
,	O
including	O
a	O
higher	O
risk	O
of	O
neutropenia	O
and	O
grade	O
3/4	O
neutropenia	O
,	O
and	O
the	O
need	O
for	O
a	O
longer	O
period	O
to	O
complete	O
the	O
front	O
-	O
line	O
chemotherapy	O
.	O

However	O
,	O
to	O
compare	O
the	O
frequency	O
and	O
severity	O
of	O
AEs	O
,	O
we	O
found	O
that	O
patients	O
in	O
the	O
paclitaxel	O
-	O
carboplatin	O
group	O
had	O
more	O
AEs	O
than	O
those	O
in	O
[P1]	O
paclitaxel	O
-	O
cisplatin	O
[P2]	O
group	O
did	O
,	O
including	O
a	O
higher	O
risk	O
of	O
neutropenia	O
and	O
grade	O
3/4	O
neutropenia	O
,	O
and	O
the	O
need	O
for	O
a	O
longer	O
period	O
to	O
complete	O
the	O
front	O
-	O
line	O
chemotherapy	O
.	O

Survival	O
Outcome	O
(	O
Table	O
5	O
)	O
Some	O
early	O
phase	O
studies	O
have	O
also	O
been	O
conducted	O
to	O
test	O
the	O
tolerability	O
and	O
efficacy	O
of	O
dose	O
-	O
dense	O
weekly	O
[P1]	O
paclitaxel	O
[P2]	O
(	B-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
and	O
triweekly	B-arm_dosage
carboplatin	O
(	B-arm_dosage
AUC	I-arm_dosage
5	I-arm_dosage
)	I-arm_dosage
with	O
other	O
agents	O
[	O
132,133	O
]	O
.	O

Survival	O
Outcome	O
(	O
Table	O
5	O
)	O
Some	O
early	O
phase	O
studies	O
have	O
also	O
been	O
conducted	O
to	O
test	O
the	O
tolerability	O
and	O
efficacy	O
of	O
dose	O
-	O
dense	O
weekly	O
paclitaxel	O
(	B-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
and	O
triweekly	B-arm_dosage
[P1]	O
carboplatin	O
[P2]	O
(	B-arm_dosage
AUC	I-arm_dosage
5	I-arm_dosage
)	I-arm_dosage
with	O
other	O
agents	O
[	O
132,133	O
]	O
.	O

The	O
current	O
low	O
-	O
dose	O
cisplatin	O
plus	O
dose	O
-	O
dense	O
paclitaxel	O
regimen	O
was	O
associated	O
with	O
lower	O
rates	O
of	O
hematologic	O
toxicities	O
compared	O
to	O
the	O
conventional	O
dose	O
-	O
dense	O
[P1]	O
paclitaxel	O
plus	O
carboplatin	O
[P2]	O
regimen	O
.	O

Consistent	O
with	O
the	O
increased	O
toxicity	O
of	O
the	O
use	O
of	O
carboplatin	O
in	O
previous	O
studies	O
[	O
136	O
]	O
,	O
the	O
incidence	O
of	O
grade	O
3/4	O
neutropenia	O
was	O
significantly	O
lower	O
in	O
the	O
[P1]	O
cisplatin	O
-	O
paclitaxel	O
[P2]	O
arm	O
than	O
in	O
that	O
of	O
the	O
carboplatin	O
-	O
paclitaxel	O
arm	O
(	O
27.8	O
%	O
versus	O
77.3	O
%	O
,	O
p	O
=	O
0.002	O
)	O
in	O
our	O
study	O
.	O

Consistent	O
with	O
the	O
increased	O
toxicity	O
of	O
the	O
use	O
of	O
carboplatin	O
in	O
previous	O
studies	O
[	O
136	O
]	O
,	O
the	O
incidence	O
of	O
grade	O
3/4	O
neutropenia	O
was	O
significantly	O
lower	O
in	O
the	O
cisplatin	O
-	O
paclitaxel	O
arm	O
than	O
in	O
that	O
of	O
the	O
[P1]	O
carboplatin	O
-	O
paclitaxel	O
[P2]	O
arm	O
(	O
27.8	O
%	O
versus	O
77.3	O
%	O
,	O
p	O
=	O
0.002	O
)	O
in	O
our	O
study	O
.	O

In	O
addition	O
,	O
other	O
parameters	O
of	O
hematological	O
examination	O
,	O
including	O
grade	O
3/4	O
anemia	O
and	O
grade	O
3/4	O
thrombocytopenia	O
also	O
favored	O
the	O
[P1]	O
cisplatin	O
-	O
paclitaxel	O
[P2]	O
regimen	O
with	O
incidence	O
of	O
5.6	O
%	O
and	O
none	O
,	O
respectively	O
,	O
compared	O
to	O
22.7	O
%	O
and	O
13.6	O
%	O
in	O
the	O
carboplatin	O
-	O
paclitaxel	O
regimen	O
in	O
the	O
current	O
study	O
.	O

In	O
addition	O
,	O
other	O
parameters	O
of	O
hematological	O
examination	O
,	O
including	O
grade	O
3/4	O
anemia	O
and	O
grade	O
3/4	O
thrombocytopenia	O
also	O
favored	O
the	O
cisplatin	O
-	O
paclitaxel	O
regimen	O
with	O
incidence	O
of	O
5.6	O
%	O
and	O
none	O
,	O
respectively	O
,	O
compared	O
to	O
22.7	O
%	O
and	O
13.6	O
%	O
in	O
the	O
[P1]	O
carboplatin	O
-	O
paclitaxel	O
[P2]	O
regimen	O
in	O
the	O
current	O
study	O
.	O

We	O
believe	O
that	O
this	O
[P1]	O
carboplatin	O
-	O
paclitaxel	O
[P2]	O
combination	O
therapy	O
-	O
related	O
hematotoxicity	O
might	O
explain	O
why	O
more	O
patients	O
in	O
the	O
carboplatin	O
-	O
paclitaxel	O
arm	O
had	O
a	O
prolongation	O
of	O
the	O
period	O
between	O
the	O
initial	O
first	O
dose	O
of	O
chemotherapy	O
and	O
the	O
final	O
dose	O
of	O
chemotherapy	O
(	O
six	O
cycles	O
of	O
chemotherapy	O
)	O
than	O
those	O
in	O
the	O
cisplatin	O
-	O
paclitaxel	O
arm	O
(	O
45	O
%	O
versus	O
11.1	O
%	O
,	O
p	O
=	O
0.018	O
)	O
.	O

We	O
believe	O
that	O
this	O
carboplatin	O
-	O
paclitaxel	O
combination	O
therapy	O
-	O
related	O
hematotoxicity	O
might	O
explain	O
why	O
more	O
patients	O
in	O
the	O
[P1]	O
carboplatin	O
-	O
paclitaxel	O
[P2]	O
arm	O
had	O
a	O
prolongation	O
of	O
the	O
period	O
between	O
the	O
initial	O
first	O
dose	O
of	O
chemotherapy	O
and	O
the	O
final	O
dose	O
of	O
chemotherapy	O
(	O
six	O
cycles	O
of	O
chemotherapy	O
)	O
than	O
those	O
in	O
the	O
cisplatin	O
-	O
paclitaxel	O
arm	O
(	O
45	O
%	O
versus	O
11.1	O
%	O
,	O
p	O
=	O
0.018	O
)	O
.	O

We	O
believe	O
that	O
this	O
carboplatin	O
-	O
paclitaxel	O
combination	O
therapy	O
-	O
related	O
hematotoxicity	O
might	O
explain	O
why	O
more	O
patients	O
in	O
the	O
carboplatin	O
-	O
paclitaxel	O
arm	O
had	O
a	O
prolongation	O
of	O
the	O
period	O
between	O
the	O
initial	O
first	O
dose	O
of	O
chemotherapy	O
and	O
the	O
final	O
dose	O
of	O
chemotherapy	O
(	O
six	O
cycles	O
of	O
chemotherapy	O
)	O
than	O
those	O
in	O
the	O
[P1]	O
cisplatin	O
-	O
paclitaxel	O
[P2]	O
arm	O
(	O
45	O
%	O
versus	O
11.1	O
%	O
,	O
p	O
=	O
0.018	O
)	O
.	O

By	O
contrast	O
,	O
the	O
[P1]	O
cisplatin	O
[P2]	O
-	O
related	O
renal	O
,	O
neural	O
,	O
and	O
gastrointestinal	O
system	O
toxicity	O
was	O
lower	O
in	O
the	O
current	O
study	O
.	O

The	O
main	O
reason	O
is	O
the	O
use	O
of	O
[P1]	O
low	O
-	O
dose	O
cisplatin	O
[P2]	O
(	B-arm_dosage
20	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
as	O
a	O
platinum	O
compound	O
in	O
the	O
platinum	O
-	O
paclitaxel	O
combination	O
therapy	O
.	O

The	O
main	O
reason	O
is	O
the	O
use	O
of	O
low	O
-	O
dose	O
cisplatin	O
(	B-arm_dosage
20	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
as	O
a	O
platinum	O
compound	O
in	O
the	O
platinum	O
-	O
[P1]	O
paclitaxel	O
[P2]	O
combination	O
therapy	O
.	O

In	O
addition	O
,	O
only	O
patients	O
who	O
underwent	O
PCS	O
with	O
surgical	O
confirmation	O
of	O
FIGO	O
IIIC	O
serous	O
-	O
type	O
ETOC	O
and	O
PPSC	O
and	O
completed	O
6	O
cycles	O
of	O
[P1]	O
dose	O
-	O
dense	O
paclitaxel	O
[P2]	O
-	O
platinum	O
compounds	O
were	O
included	O
,	O
contributing	O
to	O
the	O
risk	O
of	O
selection	O
bias	O
.	O

Our	O
study	O
found	O
that	O
[P1]	O
paclitaxel	O
[P2]	O
might	O
be	O
one	O
of	O
the	O
most	O
critical	O
components	O
for	O
the	O
successful	O
administration	O
of	O
dose	B-arm_dosage
-	I-arm_dosage
dense	I-arm_dosage
adjuvant	O
chemotherapy	O
.	O

In	O
addition	O
,	O
the	O
on	O
-	O
schedule	O
delivery	O
and	O
shortening	O
of	O
the	O
entire	O
therapeutic	O
period	O
are	O
a	O
critical	O
step	O
for	O
the	O
survival	O
benefits	O
of	O
patients	O
who	O
undergo	O
a	O
postoperative	O
adjuvant	O
dose	B-arm_dosage
-	I-arm_dosage
dense	I-arm_dosage
[P1]	O
paclitaxel	O
[P2]	O
plus	O
platinum	O
compounds	O
regimen	O
.	O

With	O
the	O
low	O
risk	O
of	O
AEs	O
,	O
shortened	O
therapeutic	O
period	O
,	O
and	O
,	O
of	O
most	O
importance	O
,	O
working	O
without	O
compromising	O
therapeutic	O
effects	O
-	O
[P1]	O
low	O
-	O
dose	O
triweekly	O
cisplatin	O
[P2]	O
plus	O
dose	O
-	O
dense	O
weekly	O
paclitaxel	O
might	O
be	O
associated	O
with	O
better	O
NHBs	O
,	O
a	O
better	O
cost	O
-	O
effectiveness	O
,	O
and	O
a	O
better	O
QOL	O
compared	O
to	O
a	O
carboplatin	O
-	O
based	O
dose	O
-	O
dense	O
paclitaxel	O
regimen	O
.	O

With	O
the	O
low	O
risk	O
of	O
AEs	O
,	O
shortened	O
therapeutic	O
period	O
,	O
and	O
,	O
of	O
most	O
importance	O
,	O
working	O
without	O
compromising	O
therapeutic	O
effects	O
-	O
low	O
-	O
dose	O
triweekly	O
cisplatin	O
plus	O
[P1]	O
dose	O
-	O
dense	O
weekly	O
paclitaxel	O
[P2]	O
might	O
be	O
associated	O
with	O
better	O
NHBs	O
,	O
a	O
better	O
cost	O
-	O
effectiveness	O
,	O
and	O
a	O
better	O
QOL	O
compared	O
to	O
a	O
carboplatin	O
-	O
based	O
dose	O
-	O
dense	O
paclitaxel	O
regimen	O
.	O

With	O
the	O
low	O
risk	O
of	O
AEs	O
,	O
shortened	O
therapeutic	O
period	O
,	O
and	O
,	O
of	O
most	O
importance	O
,	O
working	O
without	O
compromising	O
therapeutic	O
effects	O
-	O
low	O
-	O
dose	O
triweekly	O
cisplatin	O
plus	O
dose	O
-	O
dense	O
weekly	O
paclitaxel	O
might	O
be	O
associated	O
with	O
better	O
NHBs	O
,	O
a	O
better	O
cost	O
-	O
effectiveness	O
,	O
and	O
a	O
better	O
QOL	O
compared	O
to	O
a	O
[P1]	O
carboplatin	O
[P2]	O
-	O
based	O
dose	B-arm_dosage
-	I-arm_dosage
dense	I-arm_dosage
paclitaxel	O
regimen	O
.	O

With	O
the	O
low	O
risk	O
of	O
AEs	O
,	O
shortened	O
therapeutic	O
period	O
,	O
and	O
,	O
of	O
most	O
importance	O
,	O
working	O
without	O
compromising	O
therapeutic	O
effects	O
-	O
low	O
-	O
dose	O
triweekly	O
cisplatin	O
plus	O
dose	O
-	O
dense	O
weekly	O
paclitaxel	O
might	O
be	O
associated	O
with	O
better	O
NHBs	O
,	O
a	O
better	O
cost	O
-	O
effectiveness	O
,	O
and	O
a	O
better	O
QOL	O
compared	O
to	O
a	O
carboplatin	O
-	O
based	O
dose	O
-	O
dense	O
[P1]	O
paclitaxel	O
[P2]	O
regimen	O
.	O